Principia utilizes its Tailored Covalency® technology to discover and develop safe, effective and convenient oral therapies that have the potential to become standard of care for patients with autoimmune and inflammatory diseases as well as cancer. 

Phase 1
Phase 2
PRN1008: BTK inhibitor / Pemphigus
PRN1008: BTK inhibitor / ITP
PRN1371: FGFR inhibitor / Solid Tumors
PRN2246: BTK inhibitor / Multiple Sclerosis
Immunoproteasome Inhibitor: Autoimmune / Inflamm